Terug
46
43
49
14
26
Ook genoteerd als
HOCPY
OTC
Dagbereik
€ 175,79
€ 187,00
52-Weeksbereik
€ 96,42
€ 191,23
Volume
155
50D / 200D Gem.
€ 172,84
/
€ 147,75
Vorige Slotkoers
€ 175,79
Quick Summary
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (631 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 0,3 | 0,2 |
| P/B | 0,1 | 3,0 |
| ROE % | 20,8 | 3,6 |
| Net Margin % | 22,8 | 3,8 |
| Rev Growth 5Y % | 12,8 | 9,9 |
| D/E | 0,0 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 1.235,33
€ 1.194,14 – € 1.265,27
|
1,29T | 1 |
| FY2029 |
€ 1.063,64
€ 1.028,17 – € 1.089,41
|
1,20T | 1 |
| FY2028 |
€ 885,88
€ 856,34 – € 907,35
|
1,08T | 1 |
No quarterly estimates available
Earnings Surprises
Last 8 quarters
| Quarter | Est. EPS | Actual EPS | Surprise |
|---|---|---|---|
| 2026-01-30 | € 167,80 | € 1,73 | -99,0% |
| 2025-08-01 | € 1,13 | € 1,04 | -8,0% |
| 2025-05-01 | € 1,04 | € 1,03 | -1,0% |
| 2025-02-03 | € 0,99 | € 0,92 | -6,9% |
| 2024-10-31 | € 1,02 | € 1,02 | 0,0% |
| 2024-08-01 | € 0,84 | € 134,62 | +15983,6% |
| 2024-05-15 | € 0,90 | € 160,36 | +17678,3% |
| 2024-02-01 | € 0,85 | € 111,17 | +13040,7% |
Dividend History
7 yr streakYield
0,01%
Payout Ratio
0,19%
Growth (3Y)
24,05%
Growth (5Y)
13,86%
| Ex-Date | Payment Date | Amount | Yield |
|---|---|---|---|
| Mar 30, 2026 | Mar 30, 2026 | € 0,85 | 0,00% |
| Sep 30, 2025 | Nov 28, 2025 | € 0,84 | 1,18% |
| Mar 31, 2025 | Jun 02, 2025 | € 0,77 | 0,94% |
| Sep 30, 2024 | Nov 29, 2024 | € 0,31 | 0,56% |
| Mar 28, 2024 | Jun 10, 2024 | € 0,43 | 0,57% |
| Sep 28, 2023 | Nov 30, 2023 | € 0,30 | 0,78% |
| Mar 30, 2023 | Jun 01, 2023 | € 0,49 | 0,75% |
| Sep 29, 2022 | Nov 30, 2022 | € 0,31 | 0,86% |
| Mar 30, 2022 | Jun 01, 2022 | € 0,53 | 0,80% |
| Sep 29, 2021 | Nov 30, 2021 | € 0,40 | 0,51% |
| Mar 30, 2021 | Jun 01, 2021 | € 0,41 | 0,68% |
| Sep 29, 2020 | Nov 30, 2020 | € 0,43 | 0,74% |
| Mar 30, 2020 | Jun 08, 2020 | € 0,42 | 0,91% |
| Sep 27, 2019 | Nov 29, 2019 | € 0,42 | 0,99% |
| Mar 27, 2019 | Jun 03, 2019 | € 0,41 | 1,19% |
| Sep 26, 2018 | Nov 30, 2018 | € 0,40 | 1,45% |
| Mar 28, 2018 | Jun 01, 2018 | € 0,42 | 1,37% |
| Sep 27, 2017 | Nov 30, 2017 | € 0,27 | 1,17% |
| Mar 29, 2017 | Jun 01, 2017 | € 0,41 | 68,02% |
| Sep 28, 2016 | Nov 30, 2016 | € 0,30 | 198,15% |
Belangrijkste Punten
Revenue grew 12,76% annually over 5 years — strong growth
ROE of 20,82% indicates high profitability
Net margin of 22,82% shows strong profitability
Debt/Equity of 0,04 — conservative balance sheet
Generating 187,19B in free cash flow
P/E of 0,29 — trading at a low valuation
Groei
Revenue Growth (5Y)
12,76%
Revenue (1Y)11,76%
Earnings (1Y)11,43%
FCF Growth (3Y)5,45%
Kwaliteit
Return on Equity
20,82%
ROIC35,66%
Net Margin22,82%
Op. Margin54,28%
Veiligheid
Debt / Equity
0,04
Current Ratio4,90
Interest Coverage329,54
Waardering
P/E Ratio
0,29
Forward P/E0,24
P/B Ratio0,06
EV/EBITDA-0,91
Dividend Yield0,01%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 11,76% | Revenue Growth (3Y) | 10,64% |
| Earnings Growth (1Y) | 11,43% | Earnings Growth (3Y) | 9,47% |
| Revenue Growth (5Y) | 12,76% | Earnings Growth (5Y) | 12,66% |
| Profitability | |||
| Revenue (TTM) | 885,82B | Net Income (TTM) | 202,10B |
| ROE | 20,82% | ROA | 16,37% |
| Gross Margin | 86,50% | Operating Margin | 54,28% |
| Net Margin | 22,82% | Free Cash Flow (TTM) | 187,19B |
| ROIC | 35,66% | FCF Growth (3Y) | 5,45% |
| Safety | |||
| Debt / Equity | 0,04 | Current Ratio | 4,90 |
| Interest Coverage | 329,54 | ||
| Dividends | |||
| Dividend Yield | 0,01% | Payout Ratio | 0,19% |
| Dividend Growth (3Y) | 24,05% | Dividend Growth (5Y) | 13,86% |
| Consecutive Div Years | 7 yrs | ||
| Valuation | |||
| P/E Ratio | 0,29 | Forward P/E | 0,24 |
| P/B Ratio | 0,06 | P/S Ratio | 0,07 |
| PEG Ratio | 2,33 | Forward PEG | N/A |
| EV/EBITDA | -0,91 | Fwd EV/EBITDA | -1,27 |
| Forward P/S | 0,06 | Fwd Earnings Yield | 416,67% |
| FCF Yield | 314,97% | ||
| Market Cap | 59,43B | Enterprise Value | -437,25B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 885,82B | 792,63B | 723,58B | 661,47B | 547,92B |
| Net Income | 202,10B | 181,38B | 168,64B | 164,51B | 125,45B |
| EPS (Diluted) | 581,26 | 515,27 | 469,47 | 445,93 | 335,25 |
| Gross Profit | 766,25B | 687,99B | 631,86B | 567,28B | 474,98B |
| Operating Income | 480,79B | 433,45B | 346,38B | 317,02B | 263,74B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 1,23T | 1,20T | 1,03T | 992,84B | 853,29B |
| Total Liabilities | 262,65B | 241,36B | 213,72B | 203,78B | 180,88B |
| Shareholders' Equity | 974,02B | 967,76B | 818,32B | 803,85B | 688,00B |
| Total Debt | 37,28B | 29,24B | 24,58B | 21,60B | 20,75B |
| Cash & Equivalents | 533,97B | 525,16B | 405,89B | 419,40B | 334,90B |
| Current Assets | 879,73B | 856,64B | 710,16B | 682,97B | 554,58B |
| Current Liabilities | 179,51B | 168,91B | 156,10B | 147,38B | 131,61B |
Strategiescores
This stock passed the criteria for 5 strategies
Score = fit strength (0–100)
Rank = position among all matches
Custom
Cash Flow Compounder
#483 of 1049
#399 of 826
Custom
Capital Light Compounder
#70 of 220
#518 of 619
#166 of 203
Recente Activiteit
Uitgestapt
Contrarian Investing (David Dreman)
Mar 26, 2026
Uitgestapt
Defensive Investing (Benjamin Graham)
Mar 26, 2026
Ingestapt
Cash Flow Compounder
Mar 24, 2026
Ingestapt
Deep Value Investing (Seth Klarman)
Mar 24, 2026
Ingestapt
Capital Light Compounder
Mar 24, 2026
Ingestapt
Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026
Ingestapt
Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt
Defensive Investing (Benjamin Graham)
Mar 24, 2026
Ingestapt
Value Investing (Warren Buffett)
Mar 24, 2026